TTRX:NASDAQTurn Therapeutics Inc. Analysis
Data as of 2026-05-06 - not real-time
$3.80
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Turn Therapeutics is trading just above its short‑term moving averages with the 20‑day SMA providing a modest floor, while the 50‑day SMA sits slightly lower, indicating a neutral price stance. Technical momentum remains positive as the RSI hovers above the 60‑point threshold and the MACD histogram is in bullish territory, though volume has been on a downtrend, suggesting waning buying pressure.
Fundamentally, the company shows no revenue, negative earnings and a DCF‑derived fair value well below the current market price, resulting in an overvalued assessment. The balance sheet is thin, with modest cash and negligible debt, but cash burn and a high beta amplify market risk. Investors should weigh the speculative upside of the biotech pipeline against the pronounced valuation disconnect and volatility.
Fundamentally, the company shows no revenue, negative earnings and a DCF‑derived fair value well below the current market price, resulting in an overvalued assessment. The balance sheet is thin, with modest cash and negligible debt, but cash burn and a high beta amplify market risk. Investors should weigh the speculative upside of the biotech pipeline against the pronounced valuation disconnect and volatility.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Bullish MACD and RSI indicating short‑term momentum
- Price positioned just above short‑term support levels
- Decreasing trading volume raising caution on liquidity
Medium Term
1–3 yearsCautious
Model confidence: 7/10
Key Factors
- Current price far exceeds DCF fair value
- Negative earnings and zero revenue undermine fundamentals
- High volatility and beta amplify market exposure
Long Term
> 3 yearsPositive
Model confidence: 5/10
Key Factors
- Potential upside from biotech pipeline and proprietary delivery technology
- Sector long‑term growth prospects for skin and wound therapeutics
- Limited debt and a small cash reserve provide a modest runway
Key Metrics & Analysis
Financial Health
P/E Ratio-25.3
ROE-141.67%
ROA-55.90%
Debt/Equity1.72
P/B Ratio210.8
Op. Cash Flow$-2562901
Free Cash Flow$1.7M
Industry P/E26.8
Technical Analysis
TrendNeutral
RSI61.2
Support$3.09
Resistance$3.90
MA 20$3.52
MA 50$3.49
MA 200$3.94
MACDBullish
VolumeDecreasing
Fear & Greed Index90.29
Valuation
Fair Value$0.94
Target Price$8.00
Upside/Downside110.80%
GradeOvervalued
TypeValue
Risk Assessment
Beta1.35
Volatility48.36%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.